AIM: To retrospectively assess the acute and long-term toxicity using aromatase inhibitors (AI) therapy concurrently with hypofractionated radiotherapy (HFRT) in breast cancer patients. METHODS: From November 1999 to October 2007, 66 patients were treated with breast HFRT and concurrent AI. In 63 patients (95.5%), HFRT delivered a total dose of 32.5 Gy to the whole breast within 5 wk (five fractions, one fraction per week). Other fractionations were chosen in three patients for the patients' personal convenience. A subsequent boost to the tumor bed was delivered in 35 patients (53.0%). Acute toxicities were scored according to the Common Toxicity Criteria for Adverse Events v3. Late toxicity was defined as any toxicity occurring more than 6 mo after completion of HFRT and was scored according to the Late Effects Normal Tissue Task Force-Subjective, Objective, Management and Analytic scale. RESULTS: At the end of the HFRT course, 19 patients (28.8%) had no irradiation-related toxicity. Acute grade 1-2 epithelitis was observed in 46 patients (69.7%). One grade 3 toxicity (1.5%) was observed. With a median follow-up of 34 mo (range: 12-94 mo), 31 patients (47%) had no toxicity, and 35 patients (53%) presented with grade 1-2 fibrosis. No grade 3 or greater delayed toxicity was observed. CONCLUSION: We found that AI was well tolerated when given concurrently with HFRT. All toxicities were mild to moderate, and no treatment disruption was necessary. Further prospective assessment is warranted.
AIM: To retrospectively assess the acute and long-term toxicity using aromatase inhibitors (AI) therapy concurrently with hypofractionated radiotherapy (HFRT) in breast cancerpatients. METHODS: From November 1999 to October 2007, 66 patients were treated with breast HFRT and concurrent AI. In 63 patients (95.5%), HFRT delivered a total dose of 32.5 Gy to the whole breast within 5 wk (five fractions, one fraction per week). Other fractionations were chosen in three patients for the patients' personal convenience. A subsequent boost to the tumor bed was delivered in 35 patients (53.0%). Acute toxicities were scored according to the Common Toxicity Criteria for Adverse Events v3. Late toxicity was defined as any toxicity occurring more than 6 mo after completion of HFRT and was scored according to the Late Effects Normal Tissue Task Force-Subjective, Objective, Management and Analytic scale. RESULTS: At the end of the HFRT course, 19 patients (28.8%) had no irradiation-related toxicity. Acute grade 1-2 epithelitis was observed in 46 patients (69.7%). One grade 3 toxicity (1.5%) was observed. With a median follow-up of 34 mo (range: 12-94 mo), 31 patients (47%) had no toxicity, and 35 patients (53%) presented with grade 1-2 fibrosis. No grade 3 or greater delayed toxicity was observed. CONCLUSION: We found that AI was well tolerated when given concurrently with HFRT. All toxicities were mild to moderate, and no treatment disruption was necessary. Further prospective assessment is warranted.
Entities:
Keywords:
Aromatase inhibitors; Breast cancer; Hypofractionated radiotherapy; Skin toxicity
Authors: A Howell; J Cuzick; M Baum; A Buzdar; M Dowsett; J F Forbes; G Hoctin-Boes; J Houghton; G Y Locker; J S Tobias Journal: Lancet Date: 2005 Jan 1-7 Impact factor: 79.321
Authors: Beat Thürlimann; Aparna Keshaviah; Alan S Coates; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Manuela Rabaglio; Ian Smith; Andrew Wardley; Andrew Wardly; Karen N Price; Aron Goldhirsch Journal: N Engl J Med Date: 2005-12-29 Impact factor: 91.245
Authors: Cyrus Chargari; Robert Alain Toillon; Dhara Macdermed; Pierre Castadot; Nicolas Magné Journal: Lancet Oncol Date: 2009-01 Impact factor: 41.316
Authors: B Fisher; J Costantino; C Redmond; R Poisson; D Bowman; J Couture; N V Dimitrov; N Wolmark; D L Wickerham; E R Fisher Journal: N Engl J Med Date: 1989-02-23 Impact factor: 91.245
Authors: David Azria; Christel Larbouret; Severine Cunat; Mahmut Ozsahin; Sophie Gourgou; Pierre Martineau; Dean B Evans; Gilles Romieu; Pascal Pujol; Andre Pèlegrin Journal: Breast Cancer Res Date: 2004-12-07 Impact factor: 6.466